CompanyXERSNasdaqChicago, IL

Xeris Biopharma Holdings, Inc.

Xeris Biopharma commercializes Recorlev for Cushing's syndrome, Gvoke (liquid glucagon) for severe hypoglycemia, and Keveyis for primary periodic paralysis.

Stories only

SEC EDGAR ClinicalTrials.gov xerispharma.com

10-KSep 24Latest SEC filing, period to Jun 30

Sep 9Latest story

September 2026

Xeris details Phase 3 plan for weekly hypothyroidism therapy XP-8121

Sep 9PeopleXeris Biopharma Holdings, Inc.

August 2026

Xeris reports second-quarter 2026 results, tightens full-year revenue guidance

Aug 6Quarterly updatelevoketoconazole Xeris Biopharma Holdings, Inc.

July 2026

Xeris completes exchange of 2028 convertible notes, eliminates them from balance sheet

Jul 17FinancingXeris Biopharma Holdings, Inc.

June 2026

Xeris CEO John Shannon named Board chair, adds new director Kreher

Jun 30PeopleXeris Biopharma Holdings, Inc.